Pedram Razavi

24.7k total citations · 3 hit papers
192 papers, 7.4k citations indexed

About

Pedram Razavi is a scholar working on Electrical and Electronic Engineering, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Pedram Razavi has authored 192 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Electrical and Electronic Engineering, 57 papers in Pulmonary and Respiratory Medicine and 57 papers in Oncology. Recurrent topics in Pedram Razavi's work include Advancements in Semiconductor Devices and Circuit Design (60 papers), Semiconductor materials and devices (57 papers) and Cancer Genomics and Diagnostics (37 papers). Pedram Razavi is often cited by papers focused on Advancements in Semiconductor Devices and Circuit Design (60 papers), Semiconductor materials and devices (57 papers) and Cancer Genomics and Diagnostics (37 papers). Pedram Razavi collaborates with scholars based in United States, Ireland and United Kingdom. Pedram Razavi's co-authors include Isabelle Ferain, Nima Dehdashti Akhavan, Ran Yan, Jean-Pierre Colinge, Chi‐Woo Lee, Aryan Afzalian, Brendan McCarthy, Alan Blake, B. O'Neill and Richard Murphy and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Pedram Razavi

179 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanowire transistors without junctions

2010 1.8k citations Aryan Afzalian, Nima Dehdashti Akhavan et al. profile →
Performance estimation of junctionless multigate transistors

2009 455 citations Isabelle Ferain, Aryan Afzalian et al. profile →
Genome doubling shapes the evolution and prognosis of advanced cancers

2018 343 citations Craig M. Bielski, Ahmet Zehir et al. Nature Genetics profile →

Peers

Countries citing papers authored by Pedram Razavi

Since Specialization

Citations

This map shows the geographic impact of Pedram Razavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedram Razavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedram Razavi more than expected).

Fields of papers citing papers by Pedram Razavi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedram Razavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedram Razavi. The network helps show where Pedram Razavi may publish in the future.

Co-authorship network of co-authors of Pedram Razavi

This figure shows the co-authorship network connecting the top 25 collaborators of Pedram Razavi. A scholar is included among the top collaborators of Pedram Razavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedram Razavi. Pedram Razavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan 2025 ·JCO Precision Oncology ·(unknown), (unknown), Emanuela Ferraro, (unknown), (unknown), Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Elaine M. Walsh, Joshua Z. Drago	1
2	Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding 2025 ·Cancer Discovery ·(unknown), (unknown), (unknown), (unknown), (unknown), Sukrit Singh, John D. Chodera, Bo Liu, Elisa de Stanchina, Fresia Pareja, Atif A Hashmi, (unknown), Shanu Modi, Jacqueline Bromberg, Pedram Razavi, Joshua Z. Drago, Sarat Chandarlapaty	3
3	Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data 2025 ·Clinical Cancer Research ·Frederick M. Howard, Peter A. Fasching, Cesar A. Santa‐Maria, Elgene Lim, Joseph A. Sparano, Maryam B. Lustberg, Thomas Bachelot, Oleg Blyuss, Christine Brezden‐Masley, Yeon Hee Park, (unknown), (unknown), (unknown), Christoph Kurz, Patricia Domínguez Castro, Pedram Razavi	1
4	Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers 2025 ·Science Translational Medicine ·Yanyan Cai, (unknown), Fan Wu, HuiYong Zhao, (unknown), Antonio Marra, (unknown), Elizabeth O’Connell, (unknown), Matthew M. Miele, Zhuoning Li, Elisa de Stanchina, Emiliano Cocco, Pedram Razavi, Eneda Toska, Sean W. Fanning, Guotai Xu, Anna Sablina, Maurizio Scaltriti, Sarat Chandarlapaty	2
5	418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer 2024 ·Annals of Oncology ·Chun‐Ming Tsai, (unknown), Luc Cabel, (unknown), Enrico Moiso, Erika Gedvilaite, Marwa Ahmed, (unknown), (unknown), C. James Chou, (unknown), Moumita Chaki, (unknown), (unknown), (unknown), Daniel W. Ross, (unknown), Pedram Razavi	0
6	Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer 2024 ·Cancer Research ·Emanuela Ferraro, Atif J. Khan, George Plitas, Yuan Chen, (unknown), (unknown), Chau T. Dang, Mark E. Robson, Sarat Chandarlapaty, Shanu Modi, Pedram Razavi, Sherry Shen	1
7	Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach. 2024 ·Journal of Clinical Oncology ·Enrico Moiso, Emanuela Ferraro, Luc Cabel, Anton Safonov, (unknown), (unknown), Komal Jhaveri, Larry Norton, Mark E. Robson, Shanu Modi, Sarat Chandarlapaty, Pedram Razavi	1
8	Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer. 2024 ·Journal of Clinical Oncology ·Sherry Shen, Anton Safonov, (unknown), Yuan Chen, (unknown), Pedram Razavi, Komal Jhaveri	1
9	Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer 2023 ·Cell Reports ·Sung Soo Kim, (unknown), Anton Safonov, (unknown), Rajesh K. Soni, Gary K. Schwartz, (unknown), Hanina Hibshoosh, Pedram Razavi, Minah Kim, Sarat Chandarlapaty, Hee Won Yang	27
10	Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis 2023 ·Nature Communications ·Anna Skakodub, Henry Walch, Kathryn R. Tringale, (unknown), Brandon S. Imber, Harish N. Vasudevan, Bob T. Li, Nelson S. Moss, Kenny Kwok Hei Yu, Boris Mueller, Simon N. Powell, Pedram Razavi, Helena A. Yu, Jorge S. Reis‐Filho, Daniel R. Gomez, Nikolaus Schultz, Luke Pike	28
11	Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization 2023 ·Modern Pathology ·Fatemeh Derakhshan, Arnaud Da Cruz Paula, Pier Selenica, Edaise M. da Silva, Anne Grabenstetter, (unknown), Andrea Gazzo, Higinio Dopeso, Antonio Marra, (unknown), Dara S. Ross, Diana Mandelker, Pedram Razavi, Sarat Chandarlapaty, Hannah Y. Wen, Edi Brogi, Hong Zhang, Britta Weigelt, Fresia Pareja, Jorge S. Reis‐Filho	4
12	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer 2021 ·npj Breast Cancer ·Edaise M. da Silva, Pier Selenica, Mahsa Vahdatinia, Fresia Pareja, Arnaud Da Cruz Paula, Lorenzo Ferrando, Andrea Gazzo, Higinio Dopeso, Dara S. Ross, (unknown), Nadeem Riaz, Sarat Chandarlapaty, Pedram Razavi, Larry Norton, Hannah Y. Wen, Edi Brogi, Britta Weigelt, Hong Zhang, Jorge S. Reis‐Filho	18
13	Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer 2021 ·JCO Clinical Cancer Informatics ·Matthew S. Alkaitis, Monica Agrawal, Gregory J. Riely, Pedram Razavi, David Sontag	10
14	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling 2020 ·Molecular Cancer Research ·Sizhi Paul Gao, (unknown), Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, (unknown), Tripti Shrestha Bhattarai, Wenhuo Hu, M. Dorso, (unknown), Kwanghee Kim, Aphrothiti J. Hanrahan, Pedram Razavi, Brett S. Carver, Sarat Chandarlapaty, Jorge S. Reis‐Filho, Barry S. Taylor, David B. Solit	12
15	The genomic landscape of metastatic histologic special types of invasive breast cancer 2020 ·npj Breast Cancer ·Fresia Pareja, Lorenzo Ferrando, Simon Lee, Francisco Beça, Pier Selenica, David N. Brown, (unknown), Arnaud Da Cruz Paula, Mahsa Vahdatinia, Hong Zhang, Gabriele Zoppoli, Hannah Y. Wen, Edi Brogi, Mark E. Robson, Pedram Razavi, Sarat Chandarlapaty, Britta Weigelt, Jorge S. Reis‐Filho	18
16	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers 2019 ·Nature Communications ·Hatice U. Osmanbeyoglu, Fumiko Shimizu, Ángela Rynne‐Vidal, Direna Alonso‐Curbelo, Hsuan-An Chen, Hannah Y. Wen, Tsz-Lun Yeung, Petar Jelinic, Pedram Razavi, Scott W. Lowe, Samuel C. Mok, Gabriela Chiosis, Douglas A. Levine, Christina S. Leslie	18
17	Genome doubling shapes the evolution and prognosis of advanced cancers breakdown → 2018 ·Nature Genetics ·Craig M. Bielski, Ahmet Zehir, Alexander Penson, Mark T.A. Donoghue, Walid K. Chatila, Joshua Armenia, Matthew T. Chang, Alison M. Schram, Philip Jonsson, Chaitanya Bandlamudi, Pedram Razavi, Gopa Iyer, Mark E. Robson, Zsofia K. Stadler, Nikolaus Schultz, José Baselga, David B. Solit, David M. Hyman, Michael F. Berger, Barry S. Taylor	343
18	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists 2016 ·Cancer Discovery ·Weiyi Toy, Hazel M. Weir, Pedram Razavi, Mandy Lawson, Anne U. Goeppert, Anne Marie Mazzola, Aaron Smith, Joanne Wilson, Christopher J. Morrow, Wai Lin Wong, Elisa de Stanchina, Kathryn E. Carlson, (unknown), Sharmeen Uddin, Zhiqiang Li, Sean W. Fanning, John A. Katzenellenbogen, Geoffrey L. Greene, José Baselga, Sarat Chandarlapaty	269
19	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer 2016 ·Cancer Discovery ·Xiuning Le, (unknown), Pedram Razavi, Daniel J. Treacy, Flora Luo, Mahmoud Ghandi, Pau Castel, Maurizio Scaltriti, José Baselga, Levi A. Garraway	97
20	SOI gated resistor: CMOS without junctions 2009 ·J.-P. Colinge, Christopher Lee, Aryan Afzalian, Nima Dehdashti Akhavan, Ran Yan, Isabelle Ferain, Pedram Razavi, B. O'Neill, Alan Blake, Mark White, (unknown), Brendan McCarthy, R.A. Murphy	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact